Unblinding the watchmaker: cancer treatment and drug design in the face of evolutionary pressure.
Expert Opin Drug Discov
; 17(10): 1081-1094, 2022 10.
Article
en En
| MEDLINE
| ID: mdl-35997138
ABSTRACT
INTRODUCTION:
Death due to cancer is mostly associated with therapy ineffectiveness, i.e. tumor cells no longer responding to treatment. The underlying dynamics that facilitate this mutational escape from selective pressure are well studied in several other fields and several interesting approaches exist to combat this phenomenon, for example in the context of antibiotic-resistance in bacteria. AREAS COVERED Ninety percent of all cancer-related deaths are associated with treatment failure. Here, we discuss the common treatment modalities and prior attempts to overcome acquired resistance to therapy. The underlying molecular mechanisms are discussed and the implications of emerging resistance in other systems, such as bacteria, are discussed in the context of cancer. EXPERT OPINION Reevaluating emerging therapy resistance in tumors as an evolutionary mechanism to survive in a rapidly and drastically altering fitness landscape leads to novel treatment strategies and distinct requirements for new drugs. Here, we propose a scheme of considerations that need to be applied prior to the discovery of novel therapeutic drugs.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Diseño de Fármacos
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Expert Opin Drug Discov
Año:
2022
Tipo del documento:
Article
País de afiliación:
Alemania